Nasdaq apls.

WALTHAM, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will host a conference call and webcast to discuss its first quarter 2022 financial results on Wednesday, May 4, 2022 at 4:30 p.m. ET. To access …Apellis Pharmaceuticals, Inc. (APLS) Up 9.2% Since Last Earnings Report: Can It Continue? Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. …Apellis Pharmaceuticals, Inc. Common Stock (APLS) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Apellis Pharmaceuticals, Inc. APLS reported third-quarter 2023 loss of $1.17 per share, which was wider than the Zacks Consensus Estimate of a loss of 84 cents. The company had reported a loss of ...Real time Apellis Pharmaceuticals (APLS) stock price quote, stock graph, news & analysis.

On this news, shares of Apellis fell $6.27 per share, or approximately 19.6%, from a close of $32.02 per share on July 28, 2023, to close at $25.75 per share on July 31, 2023. The case is ...Contact Us U.S. markets close in 1 hour 31 minutes Apellis Pharmaceuticals, Inc. (APLS) NasdaqGS - NasdaqGS Real Time Price. Currency in USD Follow 2W 10W 9M 60.83 …WALTHAM, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that five abstracts ...

Aug 31, 2023 · Fintel reports that on September 15, 2023, Wells Fargo upgraded their outlook for Apellis Pharmaceuticals (NASDAQ:APLS) from Equal-Weight to Overweight.. Analyst Price Forecast Suggests 53.76% ... Nov 30, 2023 · APLS is trading at a 30% discount. Price $53.92. Nov 30, 2023. Fair Value $86.12. Nov 30, 2023 ... Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that it has ...Find the latest news headlines from Apellis Pharmaceuticals, Inc. Common Stock (APLS) at Nasdaq.com.NEW YORK, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Attention Apellis Pharmaceuticals, Inc. ("Apellis") (NASDAQ: APLS) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit ...CRESTWOOD, Ky. and WALTHAM, Mass., Nov. 20, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel ...

APLS Earnings Date and Information. Apellis Pharmaceuticals last released its quarterly earnings data on November 1st, 2023. The reported ($1.17) EPS for the …

Analyst's Opinion · Consensus Rating. Apellis Pharmaceuticals has received a consensus rating of Moderate Buy. · Price Target Upside/Downside. According to ...

Apellis Pharmaceuticals Inc (NASDAQ:APLS) showed a performance of 4.00% in past 30-days. Number of shares sold short was 16.23 million shares which calculate 7.13 days to cover the short interests. Wall Street analysts have assigned a consensus price target of $71.19 to the stock, which implies a rise of 32.73% to its current value.WALTHAM, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the ...Apellis Pharmaceuticals (NASDAQ:APLS) and Intra-Cellular Therapies (NASDAQ:ITCI) are both mid-cap medical companies, but which is the better stock?We will compare the two companies based on the strength of their risk, analyst recommendations, community ranking, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.3 дня назад ... The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Tags.hapabapa. Apellis Pharmaceuticals ( NASDAQ: APLS) won the FDA approval for its marketing application for lead asset pegcetacoplan on Friday as a treatment for geographic atrophy (GA) secondary to ...

(NASDAQ: APLS) Apellis Pharmaceuticals currently has 118,499,945 outstanding shares. With Apellis Pharmaceuticals stock trading at $61.58 per share, the total ...The crowded complement inhibitor field will be watching closely FDA’s decision, due Nov. 26, on C3 inhibitor pegcetacoplan from Apellis Pharmaceuticals Inc. (NASDAQ:APLS). The therapy is one of six complement inhibitors in development for the indication, with the next in line, Zimura avacincaptad pegol from Iveric bio Inc. …See historical performance and comparison. View Valuation. Research Apellis Pharmaceuticals' (Nasdaq:APLS) stock price, latest news & stock analysis. Find …Nov 1, 2023 · The firm increased its portfolio allocation in APLS by 653.58% over the last quarter. VGHCX - Vanguard Health Care Fund Investor Shares holds 5,895K shares representing 5.01% ownership of the company. 14 de dez. de 2017 ... Apellis Pharmaceuticals, Inc. [$APLS] rings the closing bell!Apellis Pharmaceuticals (NASDAQ:APLS) raised ~$150m via its initial public offering ("IPO") back in November 2017, issuing just over 10.7m share at a price of $14 per share. The company described ...Apellis Pharmaceuticals Inc (NASDAQ: APLS) revealed a comprehensive corporate restructuring plan aimed at catalyzing the growth of its flagship products, Syfovre (pegcetacoplan injection) and

WALTHAM, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will ...

Apellis Pharmaceuticals (NASDAQ:APLS) Insider Buying and Selling Activity. Current Insider Ownership Percentage 7.50%. Number Of Insiders Buying (Last 12 Months) 0. Number Of Insiders Selling (Last 12 Months) 13. Amount Of Insider Selling (Last 12 Months) $35.44 M. Get APLS Insider Trade Alerts. Want to know when executives …WALTHAM, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will ...Apellis Pharmaceuticals Inc (NASDAQ: APLS)’s stock price has dropped by -3.62 in relation to previous closing price of 49.36. Nevertheless, the company has seen a loss of -1.71% in its stock price over the last five trading days. Zacks Investment Research reported 2023-11-09 that FATE reports better-than-expected third-quarter 2023 financial results, driven by lower operating […]Bluebird bio Inc (NASDAQ:BLUE) was among the worst performers of the week after the company temporarily stalled its gene therapy studies in sickle cell disease. ... (NASDAQ:APLS) (after the close)Advertisement. Apellis Pharmaceuticals Inc. balance sheet, income statement, cash flow, earnings & estimates, ratio and margins. View APLS financial statements in full.Real time Apellis Pharmaceuticals (APLS) stock price quote, stock graph, news & analysis.Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) develops innovative treatments for diseases with unmet needs. In 2023, the FDA approved Syfovre, the only treatment for geographic atrophy (GA), a ...Find the latest news headlines from Apellis Pharmaceuticals, Inc. Common Stock (APLS) at Nasdaq.com.

Shares of APLS stock traded up $0.12 during trading hours on Monday, reaching $48.52. 498,084 shares of the company were exchanged, compared to its average volume of 2,676,809. Apellis ...

Analysts Are Betting On Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) With A Big Upgrade This Week May 13. Consensus revenue estimates increase by 57%, …

WALTHAM, Mass., March 16, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced longer-term data from ...Find the latest Financials data for Apellis Pharmaceuticals, Inc. Common Stock (APLS) at Nasdaq.com.WALTHAM, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the U.S ...... Inc. (APLS) Up 9.2% Since Last Earnings Report: Can It Continue? 3 days ago · Yahoo Finance. Apellis Pharmaceuticals' (NASDAQ:APLS) growing losses don't ...Stock Quote & Chart. NASDAQ: APLS. $61.58. Dec 1, 2023 4:00 PM EST. Change. +7.71 (+14.31%). Volume. 5,431,264. Today's Open. $53.99. Previous Close. $53.87.Nov 2, 2023 · Apellis Pharmaceuticals, Inc. APLS reported third-quarter 2023 loss of $1.17 per share, which was wider than the Zacks Consensus Estimate of a loss of 84 cents. The company had reported a loss of ... Find the latest Financials data for Apellis Pharmaceuticals, Inc. Common Stock (APLS) at Nasdaq.com.WALTHAM, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will ...31 de jul. de 2023 ... On today's stock market, APLS stock plummeted 19.6% to close at 25.75. ... *Real-time prices by Nasdaq Last Sale. Realtime quote and/or trade ...WALTHAM, Mass., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the ...Nov 19, 2023 · Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, cold agglutinin ... Apellis Pharmaceuticals, Inc. (“Apellis”) (NASDAQ:APLS) recently completed an upsized underwritten public offering of 8563830 shares of its common stock at ...

Nov 18, 2023 · A number of firms have modified their ratings and price targets on shares of Apellis Pharmaceuticals (NASDAQ: APLS) recently: 11/9/2023 – Apellis Pharmaceuticals is now covered by analysts at The Goldman Sachs Group, Inc.. They set a “buy” rating and a $74.00 price target on the stock. 11/2/2023 – Apellis Pharmaceuticals had its price target […] CRESTWOOD, Ky. and WALTHAM, Mass., April 16, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel ...Apellis Pharmaceuticals, Inc. Common Stock (APLS) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Instagram:https://instagram. is charles schwab in financial troublealbright bookstore hoursbest site to create an llcshort apple Apellis Pharmaceuticals Inc (NASDAQ: APLS) shares are trading lower amid safety concerns regarding the company's newly launched Syfovre (pegcetacoplan injection) for geographic atrophy (GA ...Wall Street Analysts Predict a 51.91% Upside in Apellis Pharmaceuticals, Inc. (APLS): Here's What You Should Know. (Zacks) Oct-25-23 07:00AM. Apellis … reits 2023efa Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) last released its quarterly earnings results on Wednesday, November 1st. The company reported ($1.17) earnings per share (EPS) for the ... vanguard target retirement 2045 fund Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is a commercial-stage biopharmaceutical company that specializes in discovering, developing, and selling therapeutic compounds that work by inhibiting ...MarketWatch IBD DJIA 35285.12 0.30% S&P 500 4554.22 0.11% U.S. 10 Yr 4/32 Yield 4.426% 0.15% Sign In Apellis Pharmaceuticals Inc. APLS (U.S.: Nasdaq) Overview News Apellis Pharmaceuticals...value. Forecast 12 Month Forward PEG Ratio. -0.44. Investors are always looking for companies with good growth prospects selling at attractive prices. One popular statistic used to identify such ...